Complex treatment of nicotine addiction: performance improvements

N.S. Antonov^1,2, G.M. Sakharova^1,2

¹Federal Research Institute for Health Organization and Informatics, Moscow

²Central Research Institute of Tuberculosis, Moscow

Tobacco use leads to the development of nicotine addiction. This addiction is characterized by the development of withdrawal syndrome during smoking cessation period. The main and most common manifestations of smoking cessation are symptoms of anxiety disorders. Besides, smokers have an increased risk of certain anxiety disorders, whereas smokers with anxiety disorders have more severe withdrawal symptoms during smoking cessation than smokers without anxiety disorders. Withdrawal syndrome exacerbation during smoking cessation is also observed in people with socially caused anxiety disorders. In this regard, anxiolytics use in the complex treatment of nicotine addiction significantly increases the smoking cessation effectiveness. Modern agent Fabomotizole has a pronounced anxiolytic effect, does not cause addiction and withdrawal syndrome after therapy discontinuation, and does not have the negative adverse events ch aracteristic of antidepressants and benzodiazepine anxiolytics. The therapeutic effect of Fabomotizole is manifested not only in the alleviation of existing anxiety-depressive symptoms, but also in the preventive effect focused on withdrawal syndrome during smoking cessation, which increases the effectiveness of treatment. In the article, the authors summarized their own experience using Fabomotizole in clinical practice.

Keywords: nicotine addiction, anxiety disorders, withdrawal symptoms in smocking cessation, treating nicotine addiction, treatment in smoking cessation, anxiolytics, Fabomotizole.

For citation: Antonov N.S., Sakharova G.M. Complex treatment of nicotine addiction: performance improvements. RMJ. 2019;12:62–68.